Two Billion Doses of AstraZeneca’s COVID-19 Vaccine Supplied to Countries Across the World Less Than 12 Months After First Approval
AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the last 11 months.
Approximately two-thirds of these have gone to low- and lower-middle-income countries, including more than 175 million doses delivered to 130 countries through the COVAX Facility.
This milestone comes just over 18 months after AstraZeneca and Oxford University formed their landmark partnership for the global development and distribution of a not-for-profit COVID-19 vaccine for the world, and less than 12 months after its first emergency authorisation in the UK.
Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our vaccine has played a key role in tackling the biggest public health emergency of our lifetime: an estimated million lives saved, 50 million infections prevented, two billion doses delivered. The numbers are remarkable, and I’d like to thank everyone who put their lives to one side to help in this incredible endeavour. While much of the world still has to be vaccinated, and there is still much more to do, today is a proud day and testament to what can be achieved when we all work together.”
Professor Sir Andrew J Pollard, Director of Oxford Vaccine Group, said: “This is a proud moment and tribute to the efforts of researchers who developed and tested the vaccine, manufacturing staff who continue to work tirelessly to make it, logistics teams who ship it to clinics in every corner of the earth, armies of vaccinators who get it in our arms, and the public who have been with us since the first clinical trial dose on 23rd April 2020.”
To date, COVID-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) is estimated to have helped prevent 50 million COVID-19 cases, five million hospitalisations, and helped save more than one million lives. From the body of evidence in clinical trials and real-world data, the vaccine has been shown to have an acceptable safety profile.
AstraZeneca continues to engage with governments, multilateral organisations and collaborators to ensure broad and equitable access to the vaccine.
- ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Read more
- Superior HealthPlan and eFamilyCare Expand Partnership to Support Medicaid Members and Caregivers in Texas Read more
- Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform Read more
- FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate Read more
- $25 Million Gift to Penn Medicine and Children’s Hospital of Philadelphia Establishes Center for Epilepsy and Neurodevelopmental Disorders Read more